Neptunus Bio

Shenzhen Neptunus Bioengineering Co., Ltd. is a listed company under Neptunus Group, founded in 1992. It is a large pharmaceutical listed company with pharmaceutical R&D and manufacturing, pharmaceutical logistics, and medical investment as its core businesses (Shenzhen Stock Exchange stock code: 000078; controlling subsidiary Neptunus Interlong HKEx stock code: 08329). Over 28 years since its founding, the company has positioned itself at the forefront of the biopharmaceutical industry, accelerated industrial chain integration, simultaneously promoted organic growth and external expansion, and maintained sustained and rapid growth in operating performance for many consecutive years. Neptunus possesses a * technological innovation system, production and quality assurance system, and market network, with two * and provincial-level enterprise technology centers, a postdoctoral workstation, and multiple modern logistics bases. The company's comprehensive competitiveness ranks among the top in China's pharmaceutical and health industry.
Neptunus has been successively selected as one of Shenzhen's Top 100 Technology Enterprises, Guangdong Province's Outstanding High-tech Enterprise, China's Top 100 Most Competitive High-tech Enterprises, and China's Top 50 Most Potential Listed Companies. Currently, the company's pharmaceutical commercial logistics industry, biopharmaceutical industry, pharmaceutical chain, and medical investment are in a stage of sustained, healthy, and high-speed growth. In 2019, the company's revenue reached 41.4 billion yuan. In the next 5 years, Neptunus will achieve new leapfrog development and strive toward the goal of 100 billion, forging ahead for public health and the development of China's pharmaceutical and medical industry, building a lasting foundation.